The Law Offices of Vincent Wong are investigating Sarepta Therapeutics,
Inc. (NASDAQ:SRPT) in relation to possible breaches of fiduciary duty by
the board of directors.
Click here to learn about the investigation: http://docs.wongesq.com/SRPT-Info-Request-Form-1068.
There is no cost or obligation to you.
On January 15, 2016, the U.S. Food and Drug Administration (the “FDA”)
released a statement by an agency advisory committee that cast
significant doubt on the approval prospects of Sarepta’s muscular
dystrophy drug eteplirsen. The agency’s internal review of eteplirsen
stated, in part, that “[a]lthough FDA is prepared to be flexible with
respect to a devastating illness with no treatment options, we cannot
approve drugs for which substantial evidence of effectiveness has not
been established.” Following this news, Sarepta stock has fallen as much
as $18.25 per share, or nearly 58 percent on January 15, 2016 during
intraday trading.
To obtain additional information, contact Vincent Wong, Esq. either via
email vw@wongesq.com, by telephone
at 212.425.1140, or visit http://docs.wongesq.com/SRPT-Info-Request-Form-1068.
Vincent Wong, Esq. is an experienced attorney that has represented
investors in securities litigations involving financial fraud and
violations of shareholder rights. Attorney advertising. Prior results do
not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160115005797/en/
Copyright Business Wire 2016